TOVX: Theriva Biologics Company Total Debt

Theriva Biologics, Inc. (TOVX) minimizes technological threats by developing tools to support microflora and combat neoplasms. The development of viral drugs relies on partnerships with scientific institutes, which increases the likelihood of acquisition by market behemoths. The confirmed price history on this chart reflects the current level of 0.00, while the business funds costly research using existing cash reserves.

TOVX Theriva Corp Company Debts (04/28/2023 - 11/01/2026)

Analytical breakdowns for Theriva Biologics (TOVX)

- stock price and consensus target price:

Share Price Theriva Corp|TOVX - Analyst Consensus Forecast

- market capitalization information:

Market Valuation Synthetic Biologics|TOVX - Total Company Value

- book value of equity indicators:

Net Asset Value per Share Theriva Biologics|TOVX - Company Book Value|Market Value to Book Value Ratio therivabio.com|TOVX - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

TOVX - Company Net Income

Summary company analytics:TOVX - Theriva Corp

Mass-produced product of Theriva Biologics

The development of VCN-01 immunotherapy requires significant capital expenditures for safety and inhibitor combinations, making the financial stability of Theriva Biologics, Inc. (TOVX) critical. The total volume of loans and bonds, reflected in the company's debt history, allows for an assessment of the balance between leverage and business viability, helping investors determine the risk of default or the potential for growth in shareholder returns.

Who Theriva Biologics, Inc. competes with